Special Issue

Immunology in Recurrent Pregnancy Loss, Preeclampsia and Infertility

Message from the Guest Editor

Pregnancy is an allograft that requires special tolerant mechanisms to preserve fetal vitality. When these mechanisms fail, what ensues is recurrent pregnancy loss, recurrent implantation failure in in vitro fertilization, and, in rare occasions, infertility. The mother's immune system plays an important role during this tolerogenic state. In this Special Issue, we will showcase studies on the immunology of normal pregnancy, recurrent pregnancy loss, infertility, and preeclampsia, as well as autoimmune and infection diseases in gestation.

Keywords

- immunology of pregnancy
- recurrent pregnancy loss
- infertility
- preeclampsia
- autoimmunity

Guest Editor

Dr. Jenny Valentina Garmendia

Institute of Molecular and Translational Medicine, Faculty of Medicine, Palacký University, 77900 Olomouc, Czech Republic

Deadline for manuscript submissions

30 June 2026



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/260017

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +4161 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).